Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962137 | 0.82 | SIRT1 (0.40) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL3643806 | 0.81 | SIRT1 (0.42) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL221270 | 0.81 | F2RL3 (0.47) | F2RL3SIRT1HDAC3HDAC4HDAC1 | |
| SCHEMBL13470875 | 0.81 | F2RL3 (0.50) | F2RL3SIRT1HDAC3HDAC4HDAC1 | |
| SCHEMBL218601 | 0.81 | F2RL3 (0.47) | F2RL3SIRT1HDAC3HDAC4HDAC1 | |
| SCHEMBL219491 | 0.81 | SIRT1 (0.51) | F2RL3SIRT1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL3734801 | 0.80 | SIRT1 (0.41) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL220075 | 0.79 | F2RL3 (0.46) | F2RL3SIRT1HDAC3HDAC4HDAC1 | |
| SCHEMBL219651 | 0.79 | F2RL3 (0.46) | F2RL3SIRT1HDAC3HDAC4HDAC1 | |
| SCHEMBL221294 | 0.78 | SIRT1 (0.49) | F2RL3SIRT1CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167510-B1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2167510-B1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829556-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2167510-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008156866-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156866-A1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012080-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | F2RL3 1546/4885SIRT1 1/4885PDE4B 2074/4885 |
| US-20110015192-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | F2RL3 2464/4885SIRT1 1/4885PDE4B 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.